Filter News
Area of Research
- (-) Fusion and Fission (4)
- (-) Nuclear Science and Technology (2)
- Advanced Manufacturing (2)
- Biology and Environment (31)
- Clean Energy (98)
- Computational Biology (1)
- Computational Engineering (3)
- Computer Science (7)
- Electricity and Smart Grid (1)
- Energy Sciences (1)
- Fusion Energy (1)
- Isotopes (5)
- Materials (37)
- Materials for Computing (4)
- Mathematics (1)
- National Security (24)
- Neutron Science (14)
- Quantum information Science (2)
- Sensors and Controls (1)
- Supercomputing (39)
News Type
News Topics
- (-) Biomedical (3)
- (-) Energy Storage (2)
- (-) Grid (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (11)
- Bioenergy (1)
- Biology (1)
- Chemical Sciences (2)
- Computer Science (2)
- Critical Materials (1)
- Decarbonization (2)
- Fossil Energy (1)
- Fusion (16)
- Isotopes (4)
- ITER (5)
- Materials (1)
- Materials Science (5)
- Microscopy (1)
- Molten Salt (3)
- Nanotechnology (1)
- Neutron Science (4)
- Nuclear Energy (33)
- Partnerships (2)
- Physics (3)
- Security (1)
- Simulation (1)
- Space Exploration (5)
- Sustainable Energy (2)
- Transformational Challenge Reactor (1)
- Transportation (2)
Media Contacts
Three researchers at ORNL have been named ORNL Corporate Fellows in recognition of significant career accomplishments and continued leadership in their scientific fields.
Oak Ridge National Laboratory scientists recently demonstrated a low-temperature, safe route to purifying molten chloride salts that minimizes their ability to corrode metals. This method could make the salts useful for storing energy generated from the sun’s heat.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.